These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25133381)

  • 21. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
    Nehme A; Zibara K
    Hypertens Res; 2017 Nov; 40(11):903-909. PubMed ID: 28680167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
    Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
    Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context.
    Ferrari R; Rosano GM
    Int J Cardiol; 2013 Jun; 166(2):286-8. PubMed ID: 23452882
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevalence of Concurrent Prescribing of ACE-Is and ARBs among Beneficiaries of Puerto Rico's Government-Sponsored Health Care Plan During 2012 and 2013.
    Figueroa-Ríos D; Hernández-Muñoz JJ; García-Albarrán A; García-Rodríguez EA; Méndez-Hernández G; Vélez-Rivera SM
    P R Health Sci J; 2017 Jun; 36(2):71-76. PubMed ID: 28622402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACE inhibitors, diabetes and cardiovascular disease.
    Gazis A; Page SR; Cockcroft JR
    Diabetologia; 1998 May; 41(5):595-7. PubMed ID: 9628279
    [No Abstract]   [Full Text] [Related]  

  • 27. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?
    Sindone A; Erlich J; Lee C; Newman H; Suranyi M; Roger SD
    Intern Med J; 2016 Mar; 46(3):364-72. PubMed ID: 26968600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Inquiry: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?
    Trietley GS; Wilson SA; Chaudhri P; Payette N; Higbea A; Nashelsky J
    J Fam Pract; 2017 Apr; 66(4):257-263. PubMed ID: 28375400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
    Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
    Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications.
    Podar T; Tuomilehto J
    Drugs; 2002; 62(14):2007-12. PubMed ID: 12269846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI; Saxena AB; Montez-Rath ME; Leng L; Chang TI; Winkelmayer WC
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice.
    Barrios V; Coca A; Escobar C; Enrique R; Rincón LM
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):159-66. PubMed ID: 22292872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.
    Wang B; Wang F; Zhang Y; Zhao SH; Zhao WJ; Yan SL; Wang YG
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):263-74. PubMed ID: 25660574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do the benefits of medications outweigh the burdens for hemodialysis patients?: comment on "Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients".
    Johansen KL
    Arch Intern Med; 2012 Apr; 172(7):593-4. PubMed ID: 22493469
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence.
    Abdellatif AA
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):251-63. PubMed ID: 22292880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes.
    Raebel MA; Dyer W; Nichols GA; Goodrich GK; Schmittdiel JA
    Pharmacotherapy; 2017 Oct; 37(10):1204-1214. PubMed ID: 28752555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.